Upadacitinib

Generic Name: Upadacitinib

Brand Names: Rinvoq

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₉F_₃N_₆O

CAS Number: 1310726-60-3

Unique Ingredient Identifier: 4RA0KN46E0

Background: Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, auto...

Indication: Upadacitinib is indicated for the treatment of moderately to severely active rheumatoid arthritis or active psoriatic arthritis in adult patients who have had an inadequate response or intolerance to one or more disease-modifying anti-rheumatic drugs (DMARDs), such as TNF blockers. In Europe, upadacitinib may be used as monotherapy or in combination with met...

Associated Conditions: Ankylosing Spondylitis (AS), Moderately to Severely Active Rheumatoid Arthritis, Moderately to Severely Active Ulcerative Colitis, Severe Atopic Dermatitis, Active Ankylosing spondylitis, Active Non-radiographic Axial Spondyloarthritis, Active Psoriatic arthritis, Moderate, active Crohn´s Disease, Moderate, refractory Atopic dermatitis, Refractory, severe Atopic Dermatitis, Severe, active Crohn´s Disease

Associated Therapies: -

Clinical Trials

Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis

Not Applicable

Recruiting

Conditions: Crohn Disease

Interventions: Drug: Upadacitinib
Drug: Vedolizumab

First Posted Date: 2023-10-23

Last Posted Date: 2023-11-22

Lead Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University

Target Recruit Count: 334

Registration Number: NCT06095596

Locations: 🇨🇳
the Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

Application of N-of-1 Rheumatoid Arthritis

Not yet recruiting

Conditions: Arthritis, Rheumatoid

First Posted Date: 2023-08-29

Last Posted Date: 2024-06-06

Lead Sponsor: Tufts Medical Center

Target Recruit Count: 18

Registration Number: NCT06016517

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

Phase 3

Recruiting

Conditions: Alopecia Areata

Interventions: Drug: Upadacitinib
Drug: Placebo

First Posted Date: 2023-08-25

Last Posted Date: 2024-12-12

Lead Sponsor: AbbVie

Target Recruit Count: 1500

Registration Number: NCT06012240

Locations: 🇺🇸
Dermatologist of Central States (DOCS) Clinical Research - Springfield /ID# 266746, Springfield, Ohio, United States
🇬🇧
Royal Sussex County Hospital /ID# 257912, Brighton, East Sussex, United Kingdom
🇺🇸
Total Skin and Beauty Dermatology Center /ID# 259539, Birmingham, Alabama, United States

and more 264 locations

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Phase 3

Recruiting

Conditions: Hidradenitis Suppurativa

Interventions: Drug: Placebo
Drug: Upadacitinib

First Posted Date: 2023-06-05

Last Posted Date: 2024-12-11

Lead Sponsor: AbbVie

Target Recruit Count: 1328

Registration Number: NCT05889182

Locations: 🇭🇺
Duplicate_Obudai Egeszsegugyi Centrum Kft. /ID# 256366, Budapest, Hungary
🇺🇸
Cahaba Dermatology & Skin Health Center /ID# 254876, Birmingham, Alabama, United States
🇺🇸
Medical Dermatology Specialists /ID# 254226, Phoenix, Arizona, United States

and more 243 locations

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

Phase 3

Recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Placebo
Drug: Upadacitinib

First Posted Date: 2023-05-06

Last Posted Date: 2024-12-16

Lead Sponsor: AbbVie

Target Recruit Count: 1000

Registration Number: NCT05843643

Locations: 🇨🇳
People's Hospital of Xinjiang Uygur Autonomous Region /ID# 266897, Urumqi, Xinjiang, China
🇺🇸
AZ Arthritis and Rheumatology /ID# 261848, Chandler, Arizona, United States
🇺🇸
AZ Arthritis and Rheumotology Research, PLLC - Flagstaff /ID# 254767, Flagstaff, Arizona, United States

and more 289 locations

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

Phase 3

Recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: Upadacitinib
Drug: Adalimumab
Drug: Adalimumab Matching Placebo
Drug: Upadacitinib Matching Placebo

First Posted Date: 2023-04-18

Last Posted Date: 2024-12-09

Lead Sponsor: AbbVie

Target Recruit Count: 480

Registration Number: NCT05814627

Locations: 🇯🇵
Hokkaido Medical Center For Rheumatic Diseases /ID# 270019, Sapporo-shi, Hokkaido, Japan
🇺🇸
AZ Arthritis and Rheumotology Research, PLLC - Flagstaff /ID# 253431, Flagstaff, Arizona, United States
🇺🇸
Arizona Arthritis and Rheumatology Research - Glendale Office /ID# 255018, Glendale, Arizona, United States

and more 210 locations

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

Phase 3

Recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: Upadacitinib

First Posted Date: 2023-03-24

Last Posted Date: 2024-12-20

Lead Sponsor: AbbVie

Target Recruit Count: 110

Registration Number: NCT05782907

Locations: 🇺🇸
Children's Specialty Group /ID# 256966, Norfolk, Virginia, United States
🇭🇺
Semmelweis Egyetem /ID# 251083, Budapest, Hungary
🇺🇸
NYU Langone Hospital - Long Island /ID# 250136, Mineola, New York, United States

and more 75 locations

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

Phase 3

Recruiting

Conditions: Juvenile Idiopathic Arthritis

Interventions: Drug: Tocilizumab
Drug: Upadacitinib

First Posted Date: 2022-11-08

Last Posted Date: 2024-10-08

Lead Sponsor: AbbVie

Target Recruit Count: 90

Registration Number: NCT05609630

Locations: 🇯🇵
Institute of Science Tokyo Hospital /ID# 251505, Bunkyo-ku, Tokyo, Japan
🇸🇪
Queen Silvia Children's Hosp /ID# 251318, Gothenburg, Vastra Gotalands Lan, Sweden
🇺🇸
New York Medical College /ID# 253437, Valhalla, New York, United States

and more 27 locations

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Upadacitinib
Drug: Dupilumab

First Posted Date: 2022-11-01

Last Posted Date: 2024-08-21

Lead Sponsor: AbbVie

Target Recruit Count: 926

Registration Number: NCT05601882

Locations: 🇺🇸
Florida International Rsrch cr /ID# 249667, Miami, Florida, United States
🇨🇳
The second affiliated hospital of Zhejiang University school of medicine /ID# 249655, Hangzhou, Zhejiang, China
🇩🇪
Universitaetsklinikum Schleswig-Holstein Campus Luebeck /ID# 249560, Lübeck, Schleswig-Holstein, Germany

and more 254 locations

A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

Phase 4

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Upadacitinib

First Posted Date: 2022-08-19

Last Posted Date: 2024-08-20

Lead Sponsor: AbbVie

Target Recruit Count: 461

Registration Number: NCT05507580

Locations: 🇮🇹
Azienda Ospedaliera di Perugia /ID# 246632, Perugia, Umbria, Italy
🇨🇦
Dermatology Research Institute - Blackfoot Trail /ID# 246703, Calgary, Alberta, Canada
🇧🇬
Medical center Cordis /ID# 253310, Pleven, Bulgaria

and more 103 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy